Parkinson's Disease
Vaccines Forecast
Parkinson's disease is a progressive, incurable neurodegenerative disorder now affecting an estimated 11.77 million people worldwide, more than triple the number recorded in 1990, and current treatment remains confined to managing symptoms rather than altering its course. That is exactly the gap the alpha-synuclein immunotherapy field is trying to close: AC Immune's ACI-7104.056, developed from AFFiRiS's pioneering PD01A/PD03A programmes, and Vaxxinity's UB-312 are both active vaccine candidates now generating early clinical signal, while Roche/Prothena's prasinezumab and Biogen's discontinued cinpanemab illustrate how much risk still sits in the more clinically advanced passive-antibody space. This is a comprehensive, patient-based commercial assessment of the Parkinson's disease vaccine opportunity across major Western markets to 2035, drawing on VacZine Analytics' long-standing, independent expertise in Chronic disease vaccine markets.
- Format
- Executive presentation + MS Excel model
- Coverage
- Major Western markets
- Indication
- Parkinson's disease, patients over 40
- Forecast horizon
- To 2035
- Approach
- Patient-based value/volume model, 3 uptake scenarios
- Base edition
- 2020
- Availability
- Syndicated / bespoke
disease worldwide (GBD 2021)
since 1990 (GBD 2021)
Parkinson's disease in 2024
now in clinical testing
A rapidly growing, still-incurable burden, now with a genuine disease-modifying target
Parkinson's disease has moved from a symptom-management story to a target-driven one. This review sets out the neuropathology and global burden behind that shift before turning to the alpha-synuclein immunotherapy landscape it has produced.
Disease overview - Parkinson's disease (PD)
Parkinson's disease is a progressive neurodegenerative disorder of the central nervous system, driven substantially by the loss of dopamine-producing neurons in the substantia nigra and by the pathological aggregation of the protein alpha-synuclein into intracellular clumps known as Lewy bodies. Cardinal motor features, resting tremor, rigidity, bradykinesia (slowing of movement) and postural instability, are joined by a wide range of non-motor symptoms, including cognitive decline, sleep disturbance, depression and autonomic dysfunction, that often precede the motor diagnosis by years. A prion-like, cell-to-cell spread of misfolded alpha-synuclein, first proposed in the staging model developed by Braak and colleagues, underpins why alpha-synuclein itself, rather than dopamine replacement, has become the field's leading disease-modifying drug target.
The scale of the disease has grown sharply since this report's original 2020 edition, when global prevalence was commonly cited at around 6.3 million. The Global Burden of Disease Study 2021 now puts global Parkinson's prevalence at 11.77 million people, up from 3.15 million in 1990, a 274% increase driven overwhelmingly by population ageing rather than any rise in underlying risk. Modelling published in The BMJ in March 2025 projects the caseload will reach 25.2 million by 2050, a further 112% increase, making Parkinson's the world's fastest-growing neurological disorder by prevalent case count. Age remains the dominant risk factor, with incidence rising roughly 35-fold between the fifth and eighth decades of life, and men remain around 1.5 times more likely to be affected than women, a disparity attributed to both a possible neuroprotective effect of oestrogen and men's historically higher occupational exposure to pesticides and industrial solvents.
That burden is expensive as well as widespread. A 2026 Michael J. Fox Foundation report, expanding the definition of cost to capture caregiving, lost productivity and pre-diagnosis expenses for the first time, put the annual US economic impact of Parkinson's disease and atypical parkinsonisms at $82.2 billion in 2024, comprising $23.8 billion in direct medical costs and $58.4 billion in indirect and non-medical costs; unless disease-modifying treatment becomes available, that figure is projected to exceed $112 billion by 2045. There remains no cure. Current treatment is confined to symptom management, principally levodopa and other dopaminergic therapies, with deep brain stimulation reserved for later-stage motor complications; nothing yet approved alters the underlying course of neurodegeneration, which is precisely the gap the alpha-synuclein immunotherapy field, covered in full in the next section, is trying to close.
Two distinct classes of alpha-synuclein immunotherapy, at two different stages of maturity
This report distinguishes plainly between active immunotherapies (vaccines that prompt a patient's own immune system to make antibodies) and passive immunotherapies (monoclonal antibodies manufactured externally and infused). The passive antibody field is clinically further advanced, yet has still to deliver an unambiguous efficacy win; the active vaccine field is earlier-stage, but is now producing its first genuine clinical signals.
-
AC ImmunePhase 2, active vaccine (VacSYn trial)ACI-7104.056 Active immunotherapy, AFFITOPE platform
Originally developed by AFFiRiS AG as PD01A and PD03A, the pioneering first-in-class alpha-synuclein vaccines that entered Phase I testing under the EU-funded SYMPATH consortium, this active immunotherapy programme was acquired in its entirety by AC Immune in July 2021, in an approximately $58.7 million all-stock deal, and re-designated ACI-7104.056. Interim results from the Phase 2 VacSYn trial, most recently updated in December 2025, showed antibody levels 16- to 20-fold above placebo and, for the first time in the field, apparent stabilisation of clinical progression (MDS-UPDRS Part 3) and multiple biomarkers, against a 2- to 3-point worsening on placebo. In August 2026, the candidate (referred to by AC Immune as ACI-7104 in its 2026 communications) received FDA Fast Track designation together with IND clearance, allowing VacSYn to expand to US trial sites; a $4 million grant from the Vijay and Marie Goradia Charitable Foundation is separately funding a two-year extension of the trial's Part 1 to track longer-term safety and efficacy. On 23 September 2026, AC Immune reported those week-100 Part 1 results, meeting the trial's safety, tolerability and immunogenicity endpoints: all 25 ACI-7104-treated patients (versus 9 on placebo, randomised 3:1) mounted an antibody response after three immunisations, with antibody penetration into cerebrospinal fluid and a preliminary biomarker signal on total alpha-synuclein in CSF; Part 1 was not designed to assess clinical efficacy, and the company now plans to finalise a Part 2 expansion design with the FDA in early 2027 as a step toward a Phase 3 decision. -
VaxxinityPhase 1 complete, Phase 2 plannedUB-312 Active immunotherapy, independently developed
An independently developed active immunotherapy, UB-312 produced a 20% reduction in aggregated, toxic alpha-synuclein in cerebrospinal fluid, versus a 3% increase on placebo, in a Phase 1 trial published in Nature Medicine in 2024, alongside a favourable safety and tolerability profile. Vaxxinity has stated its intention to advance UB-312 into Phase 2 testing on the strength of these results. -
Roche / ProthenaPhase III from 2025, passive antibodyPrasinezumab Monoclonal antibody, not a vaccine
The most clinically advanced alpha-synuclein-targeting immunotherapy of any kind, prasinezumab is an infused monoclonal antibody, a passive immunotherapy rather than a vaccine. Its Phase 2b PADOVA trial missed its primary motor-progression endpoint in December 2024 (hazard ratio 0.84, p=0.0657), though a pre-specified subgroup of levodopa-treated patients showed a materially larger effect (hazard ratio 0.79, p=0.043). Roche announced in June 2025 it would advance prasinezumab into Phase III regardless, the strongest sign yet that a regulator-facing readout for the whole alpha-synuclein class may be only a few years away, whichever modality gets there first. -
Biogen / NeurimmuneDiscontinued, February 2021Cinpanemab Monoclonal antibody, not a vaccine
A cautionary counterpoint. Biogen's cinpanemab, another passive alpha-synuclein monoclonal antibody, was discontinued in February 2021 after its Phase 2 SPARK trial failed to separate from placebo on either its primary MDS-UPDRS endpoint or DaT-SPECT imaging, a roughly $75 million write-off that remains the field's clearest reminder that targeting alpha-synuclein, in any modality, is far from guaranteed to work. -
EU SYMPATH consortiumFoundational trial infrastructureFirst-in-human AFFITOPE groundwork
The EU-funded SYMPATH consortium, in which AFFiRiS was a founding partner, ran the first-in-human trials of PD01A and PD03A and generated much of the immunogenicity and safety groundwork that AC Immune's current Phase 2 programme now builds on, a reminder of how long translational timelines run in this field.
No alpha-synuclein-targeting vaccine or antibody is approved for Parkinson's disease today, in any modality. The passive monoclonal antibody field is clinically further advanced, yet its two highest-profile programmes illustrate the risk on either side of the ledger: Biogen's cinpanemab failed outright in 2021, while Roche's prasinezumab missed its primary endpoint in 2024 and is proceeding to Phase III in 2025 on a subgroup signal rather than a clean win. Against that backdrop, the active vaccine field's first genuine clinical readouts, AC Immune's progression-slowing biomarker and MDS-UPDRS signal in December 2025, and Vaxxinity's target-engagement data in 2024, mark a meaningful, if early-stage, development. VacZine Analytics' view, reflected throughout the model, is that vaccine-specific clinical progress remains genuinely earlier-stage than the antibody space, not further ahead of it, a distinction this report treats as central rather than glossing over.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide geographic focus, spanning neuropathology and global burden, the alpha-synuclein competitive landscape, and patient-based, scenario-driven demand forecasting across major Western markets to 2035.
Patient-based value/volume demand modelling to 2035 for patients over 40, across major Western markets.
Full review of AC Immune's ACI-7104.056, Vaxxinity's UB-312 and the adjacent passive monoclonal antibody field (prasinezumab, cinpanemab).
Three uptake scenarios reflecting different rates of physician and patient adoption for a genuinely first-in-class vaccine category, including the possibility of prophylactic use.
Volume and value forecasts to 2035, reflecting pipeline progression across both active vaccine and passive antibody modalities.
Updated global burden review incorporating GBD 2021/2050 projections and the 2026 US economic burden update.
Designed as an ideal tool to aid early-stage decision making in Parkinson's vaccine positioning, investment and market entry planning.
A glimpse of the commercial model
The table below shows a partial view of the segment, geography and modality framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Segment | Geography | Modality | Status | Revenue scenario |
|---|---|---|---|---|
| Patients over 40, base uptake | Major Western markets | Active vaccine | Pre-licensure | Modelled |
| Patients over 40, upside uptake | Major Western markets | Active vaccine | Pre-licensure | Modelled |
| Prophylactic-use scenario | Major Western markets | Active vaccine | Exploratory | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All modalities | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the Parkinson's disease vaccine opportunity across a genuinely first-in-class immunotherapy category.
- Executive presentation - neuropathology, global burden, alpha-synuclein biology and full competitive review across active vaccine and passive antibody modalities
- MS-Excel patient-based value/volume forecast model - demand outputs to 2035 across three uptake scenarios for patients over 40
- Major Western market coverage - modelled individually and in aggregate
- Competitor intelligence - AC Immune's ACI-7104.056, Vaxxinity's UB-312, and the prasinezumab/cinpanemab passive-antibody context
- Updated epidemiology module - GBD 2021/2050 burden data and the 2026 US economic burden update
- Prophylactic-use scenario - commercial assessment of a preventive, pre-symptomatic use case alongside the base symptomatic-treatment forecast
- Early decision-making support - target product profile and market entry guidance for a still-forming category
Built for organisations evaluating the Parkinson's disease vaccine opportunity
Most valuable to teams assessing the Parkinson's disease immunotherapy market against their own pipeline, BD ambitions or investment thesis, at a moment when both active vaccines and passive antibodies are producing their first meaningful clinical signals.
Vaccine & biologics developers
Positioning and commercial feasibility assessment for alpha-synuclein candidates, active or passive, at any stage.
Corporate strategy & BD
Validate the size and structure of a market with no approved product yet, ahead of AC Immune's and Roche's next major readouts.
Investors & analysts
Independent, non-conflicted assessment of pipeline risk across AC Immune, Vaxxinity, Roche/Prothena and Biogen's discontinued programme.
Public health & neurology programmes
Demand modelling to support future Parkinson's immunisation and immunotherapy access planning.
Researchers & academia
Comprehensive epidemiology and R&D landscape for grant and translational alpha-synuclein research planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions for a novel, likely high-cost first-in-class biologic category.
VacZine Analytics has drawn on its long-standing expertise in Chronic diseases since our earliest editions, positioning us to revisit the Parkinson's disease vaccine opportunity now that the alpha-synuclein immunotherapy field, active vaccines and passive antibodies alike, is finally generating its first genuine clinical signals. This is a genuinely comprehensive analysis with a wide geographic focus across major Western markets, and it has been well received by clients in the field for the depth of its epidemiology, pipeline and forecasting detail. Few groups have followed this historically slow-moving, high-risk market as closely, and that recognised, independent expertise underpins everything in the analysis.
This report was last published in 2020; any refresh would incorporate current Global Burden of Disease epidemiology, the 2026 US economic burden update, and the full alpha-synuclein competitive landscape, including AC Immune's ACI-7104.056 (formerly AFFiRiS's PD01A/PD03A), Vaxxinity's UB-312, and the adjacent prasinezumab and cinpanemab passive-antibody programmes. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Parkinson's disease vaccine analysis, a briefing call is included on request.